Vaxxas
$58.0M
Funding date
Valuation / Funding
No funding history available
Funding data has not been imported for this company yet
Current Valuation Metrics
Vaxxas is currently valued at $235.6M as of August 25, 2025. The company has raised a total of $154.3M in funding.
Capital Efficiency
With a capital efficiency ratio of 1.53x, Vaxxas has achieved a valuation that is 1.53 times the total capital raised. This metric indicates room for improvement in capital deployment.
Investment Perspective
Vaxxas's valuation reflects investor confidence in the company's market position, growth potential, and ability to execute on its business model. Private market valuations are determined by primary funding rounds and secondary market transactions, which take into account financial performance, market conditions, and growth prospects.
What is Vaxxas Worth in 2025?
As of 2025, Vaxxas is valued at $235.6M, based on the company's Later Stage VC funding round in August 25, 2025. This valuation positions Vaxxas as one of the leading private companies in the sector.
Vaxxas Valuation History
Vaxxas's funding history demonstrates steady growth and investor confidence.
How Vaxxas Valuation is Determined
Private company valuations like Vaxxas's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including:
- Revenue growth and financial performance
- Market opportunity and total addressable market (TAM)
- Competitive positioning and market share
- Management team strength and execution capability
- Technology and intellectual property
- Industry trends and investor sentiment
Vaxxas Valuation FAQs
Is Vaxxas profitable?
Vaxxas has not publicly disclosed its profitability status. Many high-growth private companies prioritize market expansion and user growth over profitability in their early stages.
How does Vaxxas's valuation compare to competitors?
Vaxxas is valued at $235.6M, positioning it as a major player in the space. Secondary market pricing and private market transactions provide ongoing validation of this valuation.
When will Vaxxas IPO?
Vaxxas has not announced plans for an initial public offering. Until an IPO, investors can access Vaxxas shares through secondary market platforms.